Skip to main navigation
Skip to search
Skip to main content
Sort by
Keyphrases
Phase II Trial
100%
Rituximab
100%
Post-transplant Lymphoproliferative Disorder
100%
Rituximab Therapy
100%
Solid Organ Transplantation
100%
Kidney
40%
Median Time
40%
Complete Response
40%
Histology
20%
Lung
20%
Pancreas
20%
Transplantation
20%
B Cells
20%
Blood Pressure
20%
Bone Marrow
20%
Diffuse Large B-cell Lymphoma (DLBCL)
20%
Progressive Disease
20%
CD20-negative
20%
Delayed Diagnosis
20%
Immunosuppressive Therapy
20%
Excess Mortality
20%
Overall Response Rate
20%
Common Complications
20%
Partial Response
20%
Conventional Therapy
20%
Median Survival
20%
Extranodal Disease
20%
Central Nervous System Involvement
20%
Time to Treatment Failure
20%
Primary Extranodal
20%
Intravenous Dose
20%
Disorder Diagnosis
20%
Well Tolerated
20%
TAge
20%
Medicine and Dentistry
Rituximab
100%
Phase II Trials
100%
Posttransplant Lymphoproliferative Disease
100%
Solid Organ Transplantation
100%
B Cell
16%
Lung
16%
Intravenous Drug Administration
16%
Central Nervous System
16%
Blood Pressure
16%
Immunosuppressive Treatment
16%
Progressive Disease
16%
Mortality Rate
16%
CD20
16%
Large-Cell Lymphoma
16%
Time to Treatment
16%
Diseases
16%
Histology
16%
Median Follow Up
16%